The Myriad myPath Melanoma molecular diagnostic test was effective in helping practitioners differentiate between benign and malignant melanocytic lesions, according to results from a prospective study.
Kelly Goff, MD
Advertisement
Articles by Kelly Goff, MD
Advertisement
Latest Updated Articles
Novel Molecular Test Contributes to Definitive Diagnosis in MelanomaPublished: February 12th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5